IFN-ω蛋白

Human

Escherichia coli.

Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.

CDLPQNHGLL SRNTLVLLHQ MRRISPFLCL KDRRDFRFPQ EMVKGSQLQK AHVMSVLHEM LQIFSLFHT ERSSAAWNMT LLDQLHTGLH QLQHLETCL LQVVGEGESA GAISSPALTL RRYFQGIRVY LKEKKYSDCA WEVVRMEIMK SLFLSTNMQE RLRSKDRDLG SS

No Tag

> 97 % by SDS-PAGE and HPLC analyses.

Less than 1 EU/μg of Recombinant HumanIFN-ω as determined by LAL method.

Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human TF-1 cells is less than 0.01 ng/ml, corresponding to a specific activity of > 1.0 × 108 IU/mg.

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

P05000

3467

1. Yang LM, Xue QH, Sun L, et al. 2007. J Interferon Cytokine Res, 27: 119-27.
2. Liu L, Leaman DW, Bixby JA, et al. 1996. Biochim Biophys Acta, 1294: 55-62.
3. Adolf GR. 1990. Virology, 175: 410-7.
4. Benoit P, Maguire D, Plavec I, et al. 1993. J Immunol, 150: 707-16.